Jun. 20 at 10:39 AM
$EVH Evolent Health backs Q2 adjusted EBITDA view
$33M-
$40M
Backs FY25 adjusted EBITDA view
$135M-
$156MEVOLENT Health announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 Adjusted EBITDA guidance of
$33M-
$40M and its full year Adjusted EBITDA guidance of
$135M-
$165M.
John Johnson, Evolent's CFO, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thirds of the quarter. We remain confident in meeting or beating the expectations we set for the 2nd quarter and full year. If these trends continue through June, we would anticipate being in the top half of our range for Q2 Adjusted EBITDA."
The company also announced it signed a commitment letter with Ares Management Credit funds, securing the option to borrow additional non-dilutive capital, if needed, to address its 2025 Convertible Notes while leaving incremental working capital on its balance sheet to support Evolent's accelerating organic growth pipeline.
